Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 18Lymphoma, Large B-Cell, Diffuse 16Leukemia, Myeloid, Acute 16Hodgkin Disease 16Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lung Neoplasms 12Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Lymphoma, B-Cell 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 6Recurrence 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Congenital Abnormalities 4Waldenstrom Macroglobulinemia 3Plasmablastic Lymphoma 3Ovarian Neoplasms 3Lymphoma, Primary Effusion 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

Injections 3toripalimab 2Carboplatin 2aflutinib 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Chlorogenic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Lung Cancer × Etoposide × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡